Article Figures & Data
Figures
- FIGURE 1.
Maximum-intensity projection of PSMA PET/CT showing 2 patients with homogeneous PSMA uptake in lesions (left) and 2 patients with heterogeneous PSMA uptake in lesions (right).
- FIGURE 2.
Kaplan–Meier curve (log-rank tests) of PSA-PFS (A) and OS (B) for semiquantitative SUVmean quartiles (Q1–Q4).
- FIGURE 3.
Scatterplot of weighted regression curves of log SUVmean vs. SUVmax range, by visual heterogeneity score (homogeneous vs. heterogeneous).
- FIGURE 4.
Color-coded table of HIT scores 1–4 incorporating SUVmax range (most intense lesion) and binary visual heterogeneity with patient numbers in each group. Red = HIT score 1; yellow = HIT score 2; green = HIT score 3; blue = HIT score 4.
- FIGURE 5.
Kaplan–Meier curve (log-rank tests) of PSA-PFS (A) and OS (B) for HIT scores 1–4.
Tables
Characteristic Value n 139 Age (y) 69 (64–74) Time since diagnosis (y) 6 (3–9) ECOG status 0–1 122 (88) 2 17 (12) Baseline PSA (ng/mL) 94 (34–325) LDH (NR, 120–250 U/L) 245 (216–317) ALP (NR, 30–110 U/L) 112 (74–203) Hemoglobin (NR, 130–180 g/L) 118 (106–129) Previous systemic treatments Androgen receptor signaling inhibitors 139 (100) Docetaxel 125 (90) Cabazitaxel 88 (63) Disease volume from PSMA PET/CT <20 metastases 49 (35) ≥20 metastases 90 (65) Sites of disease on PSMA PET/CT Bone 133 (96) Nodal* 72 (52) Visceral 31 (22) ↵* Pelvic or distant.
ECOG = Eastern Cooperative Oncology Group; LDH = lactate dehydrogenase; NR = normal range; ALP = alkaline phosphatase.
Quantitative data are number and percentage. Continuous data are median and interquartile range.
Supplemental Data
Files in this Data Supplement:
